Bio-Rad Laboratories (BIO)
NYSEHealth CareMedical - DevicesSnapshot 2026-09-09
$376.97-0.83%
Close 2026-09-09 · 1-day change
NYSEHealth CareMedical - DevicesSnapshot 2026-09-09
Warn: Primary pillar under pressure — Non-GAAP operating margin between 10.0% and 12.0% in fiscal 2026: Q2 FY26 margin 11.2% vs 10.0-12.0% target.
Bio-Rad aims to stabilize revenue with growth between -3.0% and 0.5% in 2026. The company targets an operating margin near 11%, despite recent margin cuts. Activist involvement could improve efficiency and unlock value. The stock trades slightly below analyst revenue growth expectations of about 1%.
Revenue growth remains weak or declines beyond the guided range. Operating margins fail to recover and stay below 10%. Earnings estimates continue to be revised downward, signaling ongoing struggles. Activist efforts may not lead to meaningful operational improvements.
The market prices in modest revenue growth around 1% and operating margins near 11%. Recent downward revisions and a mild price pullback reflect caution. Our view aligns with these expectations but sees risk if targets are missed.
Breaks if: No meaningful operational improvements reported within 2 quarters
Breaks if: Operating margin falls below 10.0% in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a stable, long-term thesis focused on a company in the healthcare sector. While it has shown strong recent financial performance, it is currently loss-making, which adds a layer of complexity to the investment outlook.
The market appears to have priced in a stretched valuation, reflecting a premium compared to peers. There is a slight expectations gap, indicating that investors may be anticipating some challenges ahead.
Management has set ambitious targets for operating margins and revenue growth, but recent results show mixed progress. The near-term risk of missing estimates is low, but the company operates in a high-miss-rate industry, which could impact future performance.
The thesis hinges on management's ability to meet their guidance and the overall health of the healthcare sector. Key factors include potential earnings beats from sector leaders and the impact of economic conditions on demand for BIO's products.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The latest earnings beat supports the read on BIO. However, the cautious outlook raises concerns about future revenue growth.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Maintain disciplined cost management to deliver a non-GAAP operating margin between 10.0% and 12.0% for full-year 2026.
Stated as a priority in 3 of last 3 quarters. Management has consistently guided a non-GAAP operating margin range of 10.0% to 12.0% for full-year 2026, revising down from prior estimates of up to 12.5%. The actual non-GAAP operating margin was 12.5% in 2025 and is expected to be lower in 2026, indicating limited progress in margin expansion but consistent focus on this target.
“The Company continues to expect non-GAAP operating margin of approximately 10.0 to 12.0 percent.”
“The Company expects an estimated non-GAAP operating margin of approximately 10.0 to 12.0 percent compared to prior estimate of 12.0 to 12.5 percent.”
“The Company currently expects non-GAAP operating margin of approximately 10.0 to 12.0 percent for full-year 2026.”
Breaks if: YoY revenue growth falls below -3.0% in FY26
Target revenue growth between a decline of 3.0% and an increase of 0.5% for the fiscal year 2026.
In the next 1 to 3 years, BIO's performance will depend on management execution and sector trends. Not investment advice.